Free Trial
NASDAQ:EVGN

Evogene (EVGN) Stock Price, News & Analysis

$0.60
+0.01 (+0.86%)
(As of 07/19/2024 08:55 PM ET)
Today's Range
$0.59
$0.63
50-Day Range
$0.59
$0.82
52-Week Range
$0.45
$1.20
Volume
31,700 shs
Average Volume
132,876 shs
Market Capitalization
$24.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.43

Evogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
304.2% Upside
$2.43 Price Target
Short Interest
Healthy
0.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.00 out of 5 stars

Medical Sector

748th out of 898 stocks

Agricultural Chemicals Industry

9th out of 9 stocks

EVGN stock logo

About Evogene Stock (NASDAQ:EVGN)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

EVGN Stock Price History

EVGN Stock News Headlines

[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines
Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/23/2024
Today
7/22/2024
Next Earnings (Estimated)
8/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Agricultural chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:EVGN
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.43
High Stock Price Target
$3.00
Low Stock Price Target
$1.85
Potential Upside/Downside
+304.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,880,000.00
Net Margins
-233.66%
Pretax Margin
-248.19%

Debt

Sales & Book Value

Annual Sales
$5.64 million
Book Value
$0.70 per share

Miscellaneous

Free Float
38,166,000
Market Cap
$24.73 million
Optionable
Optionable
Beta
1.40
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Ofer Haviv CPA (Age 58)
    CEO & President
    Comp: $390k
  • Dr. Nir Arbel (Age 44)
    Chief Product Officer
    Comp: $228k
  • Dr. Brian Ember (Age 48)
    Chief Executive Officer of AgPlenus Ltd
    Comp: $287k
  • Dr. Elran Hillel Haber M.B.A. (Age 44)
    Ph.D., Chief Executive Officer of Biomica Ltd
    Comp: $302k
  • Mr. Amit Noam Capt. res. (Age 42)
    Chief Executive Officer of Lavie Bio Ltd.
    Comp: $136k
  • Mr. Yaron Eldad (Age 59)
    Chief Financial Officer
  • Mr. Mark Kapel (Age 47)
    Chief Technology Officer
    Comp: $276k
  • Rachel Pomerantz Gerber
    Head of Investor Relations
  • Mr. Sassi Masliah (Age 45)
    Vice President of Corporate Development
    Comp: $245k
  • Ms. Liat Foigel Wejgman
    Vice President of Human Resources

EVGN Stock Analysis - Frequently Asked Questions

How have EVGN shares performed this year?

Evogene's stock was trading at $0.84 at the beginning of the year. Since then, EVGN shares have decreased by 28.6% and is now trading at $0.5999.
View the best growth stocks for 2024 here
.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) released its earnings results on Thursday, May, 23rd. The biotechnology company reported ($0.08) earnings per share for the quarter. The biotechnology company earned $4.19 million during the quarter. Evogene had a negative trailing twelve-month return on equity of 70.96% and a negative net margin of 233.66%.

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Evogene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

This page (NASDAQ:EVGN) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners